A surface on the androgen receptor that allosterically regulates coactivator binding

Proceedings of the National Academy of Sciences of the United States of America

Volumn 104, Issue 41, 2007, Pages 16074-16079

  Estébanez Perpiñá, Eva ^a   Arnold, Leggy A ^b   Nguyen, Phuong ^a   Rodrigues, Edson Delgado ^a   Mar, Ellena ^a   Bateman, Raynard ^a   Pallai, Peter ^c   Shokat, Kevan M ^a   Baxter, John D ^a   Guy, R Kiplin ^b   Webb, Paul ^a   Fletterick, Robert J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c Bioblocks Inc   (United States)

Author keywords

Antagonist; Antiandrogens; High throughput screening; Nuclear receptors; Regulatory surface

Indexed keywords

ANDROGEN RECEPTOR; NONSTEROID ANTIINFLAMMATORY AGENT; THYROID HORMONE; TIRATRICOL;

ALLOSTERISM; ARTICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN STRUCTURE; RECEPTOR BINDING; STRUCTURE ANALYSIS; X RAY ANALYSIS;

ALLOSTERIC SITE; ANIMALS; CRYSTALLOGRAPHY, X-RAY; MICE; MODELS, MOLECULAR; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS;

EID: 35348812462     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.0708036104     Document Type: Article

References (43)

1. Laudet V, Gronemeyer H (2002) The Nuclear Receptor Facts Book (Academic, London).
2. Baxter JD, Goede P, Apriletti JW, West BL, Feng W, Mellstrom K, Fletterick RJ, Wagner RL, Kushner PJ, Ribeiro RC, et al. (2002) Endocrinology 143:517-524.
3. Weatherman RV, Fletterick RJ, Scanlan TS (1999) Annu Rev Biochem 68:559-581.
4. Nettles KW, Greene GL (2005) Annu Rev Physiol 67:309-333.
5. Rosenfeld MG, Lunyak VV, Glass CK (2006) Genes Dev 20:1405-1428.
6. Lonard DM, O'Malley BW (2006) Cell 125:411-414.
7. Borngraeber S, Budny MJ, Chiellini G, Cunha-Lima ST, Togashi M, Webb P, Baxter JD, Scanlan TS, Fletterick RJ (2003) Proc Natl Acad Sci USA 100:15358-15363.
8. Mitro N, Mak PA, Vargas L, Godio C, Hampton E, Molteni V, Kreusch A, Saez E (2007) Nature 445:219-223.
9. Dehm SM, Tindall DJ (2006) J Cell Biochem 99:333-344.
10. Lewis-Wambi JS, Jordan VC (2005) Breast Dis 24:93-105.
11. Scher HI, Sawyers CL (2005) J Clin Oncol 23:8253-8261.
12. Darimont BD (2003) Chem Biol 10:675-676.
13. Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL (1998) Science 280:1747-1749.
14. Arnold LA, Estebanez-Perpina E, Togashi M, Jouravel N, Shelat A, McReynolds AC, Mar E, Nguyen P, Baxter JD, Fletterick RJ, et al. (2005) J Biol Chem 280:43048-43055.
15. Arnold LA, Estebanez-Perpina E, Togashi M, Shelat A, Ocasio CA, McReynolds AC, Nguyen P, Baxter JD, Fletterick RJ, Webb P, Guy RK (2006) Sci STKE 2006:pl3.
16. Wang Y, Chirgadze NY, Briggs SL, Khan S, Jensen EV, Burris TP (2006) Proc Natl Acad Sci USA 103:9908-9911.
17. Rodriguez AL, Tamrazi A, Collins ML, Katzenellenbogen JA (2004) J Med Chem 47:600-611.
18. Chang CY, Abdo J, Hartney T, McDonnell DP (2005) Mol Endocrinol 19:2478-2490.
19. Hur E, Pfaff SJ, Payne ES, Gron H, Buehrer BM, Fletterick RJ (2004) PLoS Biol 2:E274.
20. Estebanez-Perpina E, Moore JM, Mar E, Delgado-Rodrigues E, Nguyen P, Baxter JD, Buehrer BM, Webb P, Fletterick RJ, Guy RK (2005) J Biol Chem 280:8060-8068.
21. Chang CY, McDonnell DP (2005) Trends Pharmacol Sci 26:225-228.
22. Heinlein CA, Chang C (2004) Endocr Rev 25:276-308.
23. He B, Wilson EM (2002) Mol Genet Metab 75:293-298.
24. He B, Gampe RT, Jr, Kole AJ, Hnat AT, Stanley TB, An G, Stewart EL, Kalman RI, Minges JT, Wilson EM (2004) Mol Cell 16:425-438.
25. Wells J, Arkin M, Braisted A, DeLano W, McDowell B, Oslob J, Raimundo B, Randal M (2003) Ernst Schering Res Found Workshop 19-27.
26. Arkin MR, Wells JA (2004) Nat Rev Drug Discovery 3:301-317.
27. Berg T (2003) Angew Chem Int Ed Engl 42:2462-2481.
28. Toogood PL (2002) Curr Opin Chem Biol 6:472-478.
29. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, et al. (2004) Science 303:844-848.
30. Flower R (2003) Nat Rev Drug Discovery 2:179-191.
31. Braverman LE, Utiger RD (2000) (Lippincott Williams & Wilkins, Philadelphia).
32. Nienaber VL, Richardson PL, Klinghofer V, Bouska JJ, Giranda VL, Greer J (2000) Nature 18:1105-1108.
33. Buchanan G, Yang M, Harris JM, Nahm HS, Han G, Moore N, Bentel JM, Matusik RJ, Horsfall DJ, Marshall VR, et al. (2001) Mol Endocrinol 15:46-56.
34. Buchanan G, Greenberg NM, Scher HI, Harris JM, Marshall VR, Tilley WD (2001) Clin Cancer Res 7:1273-1281.
35. Shi XB, Ma AH, Xia L, Kung HJ, de Vere White RW (2002) Cancer Res 62:1496-1502.
36. McPhaul MJ (2002) Mol Cell Endocrinol 198:61-67.
37. Brelivet Y, Kammerer S, Rochel N, Poch O, Moras D (2004) EMBO Rep 5:423-429.
38. Tanenbaum DM, Wang Y, Williams SP, Sigler PB (1998) Proc Natl Acad Sci USA 95:5998-6003.
39. Milhon J, Lee S, Kohli K, Chen D, Hong H, Stallcup MR (1997) Mol Endocrinol 11:1795-1805.
40. Chavez B, Vilchis F, Zenteno JC, Larrea F, Kofman-Alfaro S (2001) Clin Genet 59:185-188.
41. Lim J, Ghadessy FJ, Abdullah AA, Pinsky L, Trifiro M, Yong EL (2000) Mol Endocrinol 14:1187-1197.
42. Milhon J, Lee S, Kohli K, Chen D, Hong H, Stallcup MR (1997) Mol Endocrinol 11:1795-1805.
43. Andrews P, Krygier S, Djakiew D (2002) Cancer Chemother Pharmacol 49:179-186.